Granzyme B-mRNA expression by equine lymphokine activated killer (LAK) cells is associated with the induction of apoptosis in target cells

Characterisation of immune responses in healthy foals when a multivalent vaccine protocol was initiated at age 90 or 180 days

REASONS FOR PERFORMING STUDY

Protection from infectious disease requires antigen-specific immunity. In foals, most vaccine protocols are delayed until 6 months to avoid maternal antibody interference. Susceptibility to disease may exist prior to administration of vaccination at age 4-6 months.

OBJECTIVES

The aim of this investigation was to characterise immune activation among healthy foals in response to a multivalent vaccine protocol and compare immune responses when foals were vaccinated at age either 90 or 180 days.

STUDY DESIGN

Randomised block design.

METHODS

Twelve healthy foals with colostral transfer were blocked for age and randomly assigned to vaccination at age 90 days (treatment) or at age 180 days (control). Vaccination protocols included a 3-dose series and booster vaccine administered at age 11 months.

RESULTS

Immune response following vaccination at age 90 or 180 days was comparable for several measures of cellular immunity. Antigen specific CD4+ and CD8+ expression of interleukin-4, interferon-γ and granzyme B to eastern equine encephalomyelitis, western equine encephalomyelitis, West Nile virus, tetanus toxoid, equine influenza and equine herpesvirus-1/4 antigens were evident for both groups 30 days after initial vaccine and at age 344 days. Both groups showed a significant increase in antigen-specific immunoglobulin G expression following booster vaccine at age 11 months, thereby indicating memory immune responses.

CONCLUSIONS

The data presented in this report demonstrate that young foals are capable of immune activation following a 3-dose series with a multivalent vaccine, despite presence of maternal antibodies. Although immune activation does not automatically confer protection, several of the immune indicators measured showed comparable expression in foals vaccinated at 3 months relative to control foals vaccinated at age 6 months. In high-risk situations where immunity may be required earlier than following a conventional vaccine series, our data provide evidence that foals respond to immunisation initiated at 3 months in a comparable manner to foals initiated at an older age.

Epitope shifting of gp90-specific cellular immune responses in EIAV-infected ponies

Unlike other lentiviruses, EIAV replication can be controlled in most infected horses leading to an inapparent carrier state free of overt clinical signs which lasts for many years. While the resolution of the initial infection is correlated with the appearance of virus specific cellular immune responses, the precise immune mechanisms responsible for control of the infection are not yet identified. Since the virus undergoes rapid mutation following infection, the immune response must also adapt to meet this challenge. We hypothesize that this adaptation involves peptide-specific recognition shifting from immunodominant variable determinants to conserved immunorecessive determinants following EIAV infection. Forty-four peptides, spanning the entire surface unit protein (gp90) of EIAV, were used to monitor peptide-specific T cell responses in vivo over a six-month period following infection. Peptides were injected intradermally and punch biopsies were collected for real-time PCR analysis to monitor the cellular peptide-specific immune responses in vivo. Similar to the CMI response to HIV infection, peptide-specific T cell recognition patterns changed over time. Early post infection (1 month), immune responses were directed to the peptides in the carboxyl-terminus variable region. By six months post infection, the peptide recognition spanned the entire gp90 sequence. These results indicate that peptide recognition broadens during EIAV infection.

The determination of in vivo envelope-specific cell-mediated immune responses in equine infectious anemia virus-infected ponies

Distinct from human lentivirus infection, equine infectious anemia virus (EIAV)-infected horses will eventually enter an inapparent carrier state in which virus replication is apparently controlled by adaptive immune responses. Although recrudescence of disease can occur after immune suppression, the actual immune correlate associated with protection has yet to be determined. Therefore, EIAV provides a model for investigating immune-mediated protective mechanisms against lentivirus infection. Here, we have developed a method to monitor EIAV-envelope specific cellular immunity in vivo. An EIA carrier horse with no clinical signs infected 7 years ago and 4 related experimental ponies infected 6 months previously were used in this study. Forty-four 20-mer peptides, representing the entire surface unit protein (gp90) of EIAV, were combined into 14 peptide pools and intradermally injected into the neck of EIAV-infected horses. An identical volume of saline alone was injected into a fifteenth site as a negative control. After 48 h, those sites with palpable infiltrations were measured prior to the collection of 2mm and 4mm punch biopsies. Total RNA was extracted from each 2mm biopsy for determination of CD3 and interferon-γ (IFN-γ) mRNA expression by real-time PCR. The 4mm skin biopsies were formalin-fixed and paraffin-embedded for immunohistochemistry (IHC) staining for CD3, CD20, CD25 and MAC387 (macrophage marker). Peripheral blood mononuclear cells (PBMC) were obtained prior to the injection and tested for in vitro reactivity against the same peptides. Histological examination showed that some of the envelope peptides elicited a lymphocytic cellular infiltration at the injection site, as evidenced by positive staining for CD3. Gp90 peptide-specific increases in CD3 and IFN-γ gene expression were also detected in the injection sites. Furthermore, differences were found between in vivo and in vitro responses to gp90 specific peptides. These results demonstrate a novel method for detecting in vivo cell-mediated immune responses to EIAV-specific peptides that is readily applicable to other host/pathogen systems.

Effect of selenium status on the response of unfit horses to exercise

Exercise is known to increase reactive oxygen species and alter glutathione peroxidase activity (GPx), a selenoenzyme responsible for neutralising hydrogen peroxide. This study evaluated the effect of selenium (Se) status on the response of unfit horses to mild exercise. 25 mature horses received one of four dietary treatments for 29 weeks: low Se (LS, n=6), adequate Se (AS, sodium selenite, n=6), high organic Se (SP; Sel-Plex®, n=7) or high inorganic Se (SS, sodium selenite, n=6). Total dietary Se concentration for LS, AS, SP and SS was 0.06, 0.12, 0.3 and 0.3 mg/kg respectively. Blood samples were collected before and at 0, 4 and 24 h after a 36 min exercise test covering 4.41 km. Blood samples were evaluated for blood GPx, pro-inflammatory cytokine expression, serum malondialdehyde (MDA), creatine kinase (CK), aspartate aminotransferase (AST) and blood pro-inflammatory cytokine expression. Data were analysed as ANOVA with repeated measures. Prior to the exercise test blood Se was higher (P<0.01) for SP and SS than AS and LS. An effect of treatment and treatment×time (P<0.05) existed for GPx. Post-exercise GPx decreased in LS and did not recover by 24 h while remaining unchanged in AS. GPx increased in SP and decreased in SS post-exercise, but both returned to pre-values at 24 h. Serum MDA was elevated at 24 h (P<0.05), but unaffected by treatment. Serum CK and AST were unaffected by Se status (P≯0.05). Pro-inflammatory cytokine expression was unaffected by Se status, although tumour necrosis factor alpha decreased immediately after exercise followed by an increase post-exercise while granzyme B was elevated immediately post-exercise (time, P<0.05). Overall Se status had minimal effects on exercise response in unfit horses. The differences in post-exercise GPx response may warrant further investigation.